Showing results (301-310 of 322) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|August 24, 2017
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapyHyungwoo Cho, Dok Hyun Yoon, Jung Bok Lee, et al.
International Journal of Hematology|September 5, 2003
Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trialMyung-Ju Ahn, Jung-Hye Choi, Young-Yeul Lee, et al.
Cancer Genetics and Cytogenetics|March 3, 2010
Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemiaSoo-Mee Bang, Ji-Weon Seo, Kyung Un Park, et al.
Annals of Hematology|September 13, 2013
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patientsKihyun Kim, Seok Jin Kim, Verena Voelter, et al.
Cancer Communications (London, England)|October 18, 2019
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
International Journal of Hematology|October 16, 2012
Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL)Sung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Leukemia & Lymphoma|July 22, 2014
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of LymphomaGyeong-Won Lee, Se-Il Go, Seok-Hyun Kim, et al.
Journal of Hematology & Oncology|August 15, 2012
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, et al.
The American Journal of Gastroenterology|February 2, 2023
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneDo Young Kim, Yu Ri Kim, Cheolwon Suh, et al.
Cancer Science|September 14, 2010
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Pageof 33